{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T21:10:10Z","timestamp":1736889010698,"version":"3.33.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["8247104651, 82160129"],"award-info":[{"award-number":["8247104651, 82160129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of Science and Technology in Gansu province","award":["22ZD6FA054"],"award-info":[{"award-number":["22ZD6FA054"]}]},{"name":"Key Talents Project of Gansu Province","award":["2019RCXM020"],"award-info":[{"award-number":["2019RCXM020"]}]},{"name":"Science and Technology Project of Chengguan District of Lanzhou City","award":["2020SHFZ0039, 2020JSCX0073"],"award-info":[{"award-number":["2020SHFZ0039, 2020JSCX0073"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital","award":["CY2017-ZD01"],"award-info":[{"award-number":["CY2017-ZD01"]}]},{"name":"Medical Research Innovation Ability Improvement Project of Lanzhou University","award":["lzuyxcx-2022-160"],"award-info":[{"award-number":["lzuyxcx-2022-160"]}]},{"name":"Excellent Textbook Cultivation Project of Lanzhou University","award":["lzuyxcx-2022-45"],"award-info":[{"award-number":["lzuyxcx-2022-45"]}]},{"name":"English Curriculum Construction and Cultivation Project of Lanzhou University","award":["lzuyxcx-2022-45"],"award-info":[{"award-number":["lzuyxcx-2022-45"]}]},{"name":"Gansu Province Innovation Driven Assistance Project","award":["GXH20230817-14"],"award-info":[{"award-number":["GXH20230817-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13469-6","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:44:01Z","timestamp":1736844241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting"],"prefix":"10.1186","volume":"25","author":[{"given":"Lijuan","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jize","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weigao","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinying","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jike","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"7","key":"13469_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, et al. Guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw. 2017;15(7):883\u201393. https:\/\/doi.org\/10.6004\/jnccn.2017.0117","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"13469_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11547-024-01757-3","volume":"129","author":"C Becherini","year":"2024","unstructured":"Becherini C, et al. Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature. Radiol Med. 2024;129(3):457\u201366. https:\/\/doi.org\/10.1007\/s11547-024-01757-3","journal-title":"Radiol Med"},{"key":"13469_CR3","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz M, Cove\u00f1as R. The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers. 2020;12(9). https:\/\/doi.org\/10.3390\/cancers12092682","DOI":"10.3390\/cancers12092682"},{"issue":"5","key":"13469_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.6004\/jnccn.2004.0038","volume":"2","author":"JP Stoutenburg","year":"2004","unstructured":"Stoutenburg JP, Raftopoulos H. Antiemetic studies on the NK1 receptor antagonist aprepitant. J Natl Compr Canc Netw. 2004;2(5):491\u20137. https:\/\/doi.org\/10.6004\/jnccn.2004.0038","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"13469_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","volume":"20","author":"M Aapro","year":"2015","unstructured":"Aapro M, et al. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015;20(4):450\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2014-0229","journal-title":"Oncologist"},{"key":"13469_CR6","doi-asserted-by":"publisher","unstructured":"Yang LQ, et al. Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: a randomized, double-blind, phase III study. Eur J Cancer Care. 2017;26(6). https:\/\/doi.org\/10.1111\/ecc.12668","DOI":"10.1111\/ecc.12668"},{"key":"13469_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2018.02.001","volume":"124","author":"M Di Maio","year":"2018","unstructured":"Di Maio M, et al. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;124:21\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"13469_CR8","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00520-018-4242-x","volume":"26","author":"C Weinstein","year":"2018","unstructured":"Weinstein C, et al. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. Support Care Cancer. 2018;26(11):3773\u201380. https:\/\/doi.org\/10.1007\/s00520-018-4242-x","journal-title":"Support Care Cancer"},{"issue":"4","key":"13469_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1470-2045(15)00615-4","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann CH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol. 2016;17(4):509\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(15)00615-4","journal-title":"Lancet Oncol"},{"issue":"4","key":"13469_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mds541","volume":"24","author":"H Saito","year":"2013","unstructured":"Saito H, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2013;24(4):1067\u201373. https:\/\/doi.org\/10.1093\/annonc\/mds541","journal-title":"Ann Oncol"},{"key":"13469_CR11","doi-asserted-by":"publisher","unstructured":"Herrstedt J, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2023;9(2). https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","DOI":"10.1016\/j.esmoop.2023.102195"},{"issue":"24","key":"13469_CR12","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397. https:\/\/doi.org\/10.1200\/jco.20.01296","journal-title":"J Clin Oncol"},{"key":"13469_CR13","doi-asserted-by":"publisher","unstructured":"Si X, et al. Retrospective analysis of real-world prescribing data for managing cisplatin\u2010based chemotherapy\u2010induced nausea and vomiting in China. Cancer Med. 2024;13(6). https:\/\/doi.org\/10.1002\/cam4.7121","DOI":"10.1002\/cam4.7121"},{"issue":"1","key":"13469_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2016;27(1):172\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv482","journal-title":"Ann Oncol"},{"key":"13469_CR15","doi-asserted-by":"publisher","unstructured":"Gao A, et al. Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy. BMC Cancer. 2023;23(1). https:\/\/doi.org\/10.1186\/s12885-023-11070-3","DOI":"10.1186\/s12885-023-11070-3"},{"issue":"7","key":"13469_CR16","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1007\/s12325-023-02537-7","volume":"40","author":"RM Navari","year":"2023","unstructured":"Navari RM, et al. Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy. Adv Therapy. 2023;40(7):3217\u201326. https:\/\/doi.org\/10.1007\/s12325-023-02537-7","journal-title":"Adv Therapy"},{"key":"13469_CR17","doi-asserted-by":"publisher","unstructured":"Weinstein C, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. BMC Cancer. 2020;20(1). https:\/\/doi.org\/10.1186\/s12885-020-07259-5","DOI":"10.1186\/s12885-020-07259-5"},{"issue":"1","key":"13469_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","volume":"22","author":"H Takemoto","year":"2016","unstructured":"Takemoto H, et al. Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. Int J Clin Oncol. 2016;22(1):88\u201395. https:\/\/doi.org\/10.1007\/s10147-016-1022-9","journal-title":"Int J Clin Oncol"},{"key":"13469_CR19","doi-asserted-by":"publisher","unstructured":"Yang Q, et al. Fosaprepitant weekly vs every 3 weeks for the prevention of concurrent chemoradiotherapy\u2013induced nausea and vomiting. JAMA Netw Open. 2023;6(7). https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26127","DOI":"10.1001\/jamanetworkopen.2023.26127"},{"issue":"11","key":"13469_CR20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/jco.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2014EASE. J Clin Oncol. 2011;29(11):1495\u2013501. https:\/\/doi.org\/10.1200\/jco.2010.31.7859","journal-title":"J Clin Oncol"},{"issue":"6","key":"13469_CR21","doi-asserted-by":"publisher","first-page":"e27690","DOI":"10.1002\/pbc.27690","volume":"66","author":"J Mora","year":"2019","unstructured":"Mora J, et al. Pharmacokinetics\/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. Pediatr Blood Cancer. 2019;66(6):e27690. https:\/\/doi.org\/10.1002\/pbc.27690","journal-title":"Pediatr Blood Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13469-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T20:31:05Z","timestamp":1736886665000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13469"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13469-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This registry-based study received ethical approval from the Ethics Committee of the Second Hospital of Lanzhou University. All participants voluntarily enrolled in the study and gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}